About the Study

Recurrent or Progressive Low-Grade Glioma: A Study to Compare Treatment with the Drug Selumetinib Alone vs. Selumetinib and Vinblastine

Study participants must be ages 2 through 25 and are suspected of having progressive or recurrent low-grade glioma (LGG). This study looks at how well selumetinib and vinblastine work when given together to children and young adults with recurrent or progressive LGGs. Vinblastine is often given to children with progressive or recurrent LGGs. Selumetinib is a drug that works by blocking a protein (a basic building block of the human body) that lets cancer cells grow without stopping. Early studies with selumetinib have had some success in treating patients with LGG that came back after a first attempt at treatment. However, the use of selumetinib in children and young adults with recurrent or progressive LGG is considered experimental because selumetinib has not yet been FDA approved for this type of cancer.

Interested in learning more?

Full Study Name: ACNS1931 - A Phase 3 Study of Selumetinib or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations